IONS Form 4: Schneider Exercises Options and Sells Shares Under 10b5-1 Plan
Rhea-AI Filing Summary
Eugene Schneider, EVP and Chief Clinical Development Officer of Ionis Pharmaceuticals (IONS), reported option exercise and subsequent share sales executed on 09/03/2025. Schneider exercised a non-qualified stock option to acquire 19,658 shares at an exercise price of $53.77, which increased his beneficial ownership to 71,165 shares. He then sold 12,455 shares at a weighted average price of $60.4608, reducing ownership to 58,710, and sold an additional 7,203 shares at a weighted average price of $61.4163, bringing beneficial ownership to 51,507 shares. The sales were made pursuant to a Rule 10b5-1 trading plan adopted on May 2, 2025. The Form 4 includes weighted-average price ranges for the sales and an undertaking to provide transaction price breakdowns on request.
Positive
- Exercise and sales disclosed transparently with weighted-average prices and offered breakdowns on request
- Sales executed under a Rule 10b5-1 trading plan, indicating pre-established trading arrangements
Negative
- None.
Insights
TL;DR: Insider exercised options and sold a portion of shares under a 10b5-1 plan, realizing proceeds above the exercise price.
The reporting shows a standard option exercise followed by systematic sales under a pre-established Rule 10b5-1 plan. Schneider acquired 19,658 shares via exercise at $53.77 and sold 19,658 shares in two tranches (12,455 and 7,203) at weighted average prices of $60.4608 and $61.4163 respectively. The sales generated proceeds above the exercise price, suggesting a net gain on the exercised options before taxes and fees. The filing explicitly discloses price ranges and offers to provide granular sale-by-sale pricing on request, which supports transparency.
TL;DR: Transactions comply with Rule 10b5-1 procedures and include adequate disclosure of pricing ranges.
The Form 4 indicates compliance with a written 10b5-1 trading plan adopted May 2, 2025, and provides weighted-average pricing with ranges and an undertaking to supply detailed breakdowns. This level of disclosure aligns with good governance practices for insider transactions by clarifying that sales were pre-planned rather than opportunistic. No additional governance issues or departures are disclosed in the filing.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Non-Qualified Stock Option (right to buy) | 19,658 | $0.00 | -- |
| Exercise | Common Stock | 19,658 | $53.77 | $1.06M |
| Sale | Common Stock | 12,455 | $60.4608 | $753K |
| Sale | Common Stock | 7,203 | $61.4163 | $442K |
Footnotes (1)
- Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on May 2, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.1862 to $61.14 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.21 to $61.66 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4.
